{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:29Z","timestamp":1791219209944,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":232,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.rmcr.2020.101197","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T02:10:49Z","timestamp":1598321449000},"page":"101197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis"],"prefix":"10.1016","volume":"31","author":[{"given":"Ryunosuke","family":"Ooi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tobino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-849X","authenticated-orcid":false,"given":"Mitsukuni","family":"Sakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Sueyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2020.101197_bib1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jtho.2019.03.021","article-title":"The landscape of actionable molecular alterations in immunomarker-defined large-cell carcinoma of the lung","volume":"14","author":"Anthony","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2020.101197_bib2","series-title":"WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015"},{"key":"10.1016\/j.rmcr.2020.101197_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2020.101197_bib4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2020.101197_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.rmcr.2020.101197_bib6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2020.101197_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2020.101197_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmcr.2020.101197_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.rmcr.2020.101197_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2020.101197_bib11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.rmcr.2020.101197_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2020.101197_bib13","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response tomanagement","volume":"3","author":"FoppenMH","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmcr.2020.101197_bib14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/hepr.12846","article-title":"Factors predictive of the efficacy of bezafibrate therapy in patients with primary sclerosing cholangitis","volume":"47","author":"Mizuno","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.rmcr.2020.101197_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jjco\/hyw167","article-title":"Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab","volume":"47","author":"Tanaka","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2020.101197_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.rmcr.2020.101197_bib17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.rmcr.2020.101197_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.rmcr.2020.101197_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.022","article-title":"Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer","volume":"115","author":"Fouchard","year":"2019","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.rmcr.2020.101197_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.rmcr.2020.101197_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen","year":"2019","journal-title":"Semin. Diagn. Pathol."},{"issue":"3","key":"10.1016\/j.rmcr.2020.101197_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J. Gastroenterol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007120304111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007120304111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:05:26Z","timestamp":1761959126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007120304111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":22,"alternative-id":["S2213007120304111"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2020.101197","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2020.101197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101197"}}